Amryt Pharma (Amryt Pharma) LT-Debt-to-Total-Asset : 0.29 (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Amryt Pharma's long-term debt to total assests ratio for the quarter that ended in Sep. 2022 was 0.29.

Amryt Pharma's long-term debt to total assets ratio increased from Sep. 2021 (0.23) to Sep. 2022 (0.29). It may suggest that Amryt Pharma is progressively becoming more dependent on debt to grow their business.

Amryt Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Amryt Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma LT-Debt-to-Total-Asset Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.13

0.24

0.34

0.35

0.24

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.23	0.24	0.26	0.28	0.29

Amryt Pharma LT-Debt-to-Total-Asset Calculation

Amryt Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )	/	Total Assets (A: Dec. 2021 )
	=	199.183	/	816.057
	=	0.24

Amryt Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

LT Debt to Total Assets (Q: Sep. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2022 )	/	Total Assets (Q: Sep. 2022 )
	=	211.825	/	736.875
	=	0.29

Amryt Pharma (NAS:AMYT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Amryt Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).